Objective: to investigate the incidence of invasive breast cancer (IBC) in pre- and postmenopausal women treated with T therapy and T in combination with E (T/E)

• 2,377 pre- and post-menopausal women were treated with T or T/E implants.
• Total cases divided by the total sample size and years in study was expressed as an incidence per 100,000 person-years.
• The BC incidence was compared with age-specific Surveillance Epidemiology and End Results (SEER) incidence rates.

Conclusions: T and/or T/E pellet implants significantly reduced the incidence of breast cancer in pre- and post-menopausal women. The addition of E did not increase the incidence over using T alone.

To read the case study please click HERE

Donovitz G, Cotten M. Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study. Eur J Breast Health. 2021 Mar 31;17(2):150-156. doi: 10.4274/ejbh.galenos.2021.6213. PMID: 33870115; PMCID: PMC8025725.

—

Objective: to investigate the incidence of IBC in pre- and postmenopausal women (presenting with symptoms of androgen deficiency) treated with subcutaneous testosterone implants or testosterone implants combined with anastrozole. 

• 10-year prospective cohort study 
• Incidence rates on testosterone therapy were compared to age-specific Surveillance Epidemiology and End Results (SEER) incidence rates and historical controls.

Conclusions: Long-term therapy with subcutaneous testosterone, or testosterone combined with anastrozole, did not increase the incidence of invasive breast cancer.

To read the case study please click HERE

Donovitz G, Cotten M. Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study. Eur J Breast Health. 2021 Mar 31;17(2):150-156. doi: 10.4274/ejbh.galenos.2021.6213. PMID: 33870115; PMCID: PMC8025725.